CA2677455A1 - Recombinant antigens of human cytomegalovirus (hcmv) - Google Patents

Recombinant antigens of human cytomegalovirus (hcmv) Download PDF

Info

Publication number
CA2677455A1
CA2677455A1 CA002677455A CA2677455A CA2677455A1 CA 2677455 A1 CA2677455 A1 CA 2677455A1 CA 002677455 A CA002677455 A CA 002677455A CA 2677455 A CA2677455 A CA 2677455A CA 2677455 A1 CA2677455 A1 CA 2677455A1
Authority
CA
Canada
Prior art keywords
hcmv
seq
antigen
nucleotide sequence
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002677455A
Other languages
English (en)
French (fr)
Inventor
Nicola Gargano
Elisa Beghetto
Andrea Spadoni
Francesca DE PAOLIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2677455A1 publication Critical patent/CA2677455A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • G01N2333/04—Varicella-zoster virus
    • G01N2333/045—Cytomegalovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
CA002677455A 2007-02-07 2008-02-05 Recombinant antigens of human cytomegalovirus (hcmv) Abandoned CA2677455A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07101864.2 2007-02-07
EP07101864 2007-02-07
PCT/EP2008/000876 WO2008095677A1 (en) 2007-02-07 2008-02-05 Recombinant antigens of human cytomegalovirus (hcmv)

Publications (1)

Publication Number Publication Date
CA2677455A1 true CA2677455A1 (en) 2008-08-14

Family

ID=38229391

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002677455A Abandoned CA2677455A1 (en) 2007-02-07 2008-02-05 Recombinant antigens of human cytomegalovirus (hcmv)

Country Status (13)

Country Link
US (1) US20100068229A1 (enExample)
EP (1) EP2114991A1 (enExample)
JP (1) JP2010517544A (enExample)
KR (1) KR20090126256A (enExample)
CN (1) CN101605808A (enExample)
AU (1) AU2008213356A1 (enExample)
BR (1) BRPI0807095A2 (enExample)
CA (1) CA2677455A1 (enExample)
EA (1) EA200970731A1 (enExample)
IL (1) IL200187A0 (enExample)
MX (1) MX2009008248A (enExample)
SG (1) SG178761A1 (enExample)
WO (1) WO2008095677A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012015523A2 (pt) 2009-12-23 2017-04-18 4-Antibody Ag membros de ligação do citomegalovirus humano, composição contendo os mesmos, método de tratamento, moléculas de anticorpo, método de produção, molecular de ácido nucléico, célula hospedeira, e, método de neutralização do hcmv.
JP5712513B2 (ja) * 2010-07-07 2015-05-07 富士レビオ株式会社 ヒトサイトメガロウイルス感染の検出方法
AU2012207454B2 (en) * 2011-01-18 2016-11-17 Prionics Ag Methods for amplification and detection of prions
CN102816246B (zh) * 2012-09-04 2014-07-23 成都蓉生药业有限责任公司 一种人巨细胞病毒免疫原融合蛋白及其制备方法和用途
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11174322B2 (en) 2017-07-24 2021-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies and peptides to treat HCMV related diseases
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL60184A (en) * 1979-05-31 1984-05-31 Schering Ag Process for the specific cleavage of protein sequences from proteins
JPH01125328A (ja) * 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
CA2050425A1 (en) * 1990-09-03 1992-03-04 Yoshiaki Uda Pharmaceutical composition and its mucous use
SG48365A1 (en) * 1992-05-23 1998-04-17 Smithkline Beecham Biolog Combined vaccines comprising hepatitis b surface antigen and other antigens
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
US5846806A (en) 1994-07-29 1998-12-08 American Cyanamid Company Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression
DK0960336T3 (da) * 1996-07-12 2003-02-10 Organon Teknika Bv Peptidreagens til påvisning af humant cytomelagovirus (CMV)
US6306404B1 (en) * 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
AT408615B (de) * 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
WO2003010198A1 (en) 2001-07-26 2003-02-06 Kenton Srl Identification of specific tumour antigens by selection of cdna libraries with sera and use of said antigens in diagnostic techniques

Also Published As

Publication number Publication date
KR20090126256A (ko) 2009-12-08
BRPI0807095A2 (pt) 2014-04-22
IL200187A0 (en) 2010-04-15
MX2009008248A (es) 2009-08-12
AU2008213356A1 (en) 2008-08-14
US20100068229A1 (en) 2010-03-18
EA200970731A1 (ru) 2010-02-26
JP2010517544A (ja) 2010-05-27
WO2008095677A1 (en) 2008-08-14
SG178761A1 (en) 2012-03-29
EP2114991A1 (en) 2009-11-11
CN101605808A (zh) 2009-12-16

Similar Documents

Publication Publication Date Title
US20100068229A1 (en) Recombinant antigens of human cytomegalovirus (hcmv)
US7867503B2 (en) Chimeric recombinant antigens of Toxoplasma gondii
JP4612071B2 (ja) エプスタイン−バールウイルスペプチド及び該ペプチドに対する抗体
JP3401022B2 (ja) ヒトパピローマウイルス１８のタンパク質における血清反応性エピトープ
US5753233A (en) Seroreactive epitopes on proteins of human papilloma-virus (HPV) 18
JP2000514300A (ja) ヒトサイトメガロウイルス（ｃｍｖ）を検出するためのペプチド試薬
HK1135116A (en) Recombinant antigens of human cytomegalovirus (hcmv)
US6319667B1 (en) Diagnostics and therapy of diseases associated with HHV-8 infections
Jalkanen et al. COVID-19 mRNA vaccine induced antibody responses and neutralizing antibodies against three SARS-CoV-2 variants 2
CN113493494B (zh) Eb病毒balf3蛋白的抗原表位
WO1999061909A2 (en) Methods and compositions for the detection of human herpesvirus
JP2004242599A (ja) Ｃｄ８＋細胞傷害性ｔリンパ球エピトープペプチド及びその用途
JP2016503011A (ja) レプトスピラ症の診断および処置のための方法およびタンパク質抗原の組成物
NO319698B1 (no) Hestearteritt-virus peptid eller peptidkonjugat omfattende en eller flere epitoper i stand til a fremkalle en immunrespons i dyr
Lang et al. Generation of monoclonal antibodies directed against the immunogenic glycoprotein K8. 1 of human herpesvirus 8
CN110967483B (zh) 恶性卡他热病毒的检测试剂盒、制备方法及其用途
CN113493495B (zh) Eb病毒balf4蛋白的抗原表位
JP2003043044A (ja) 抗体捕捉法による抗体の免疫学的測定方法
JP2010158251A (ja) Ｈｃｍｖウイルスに対して特異的な抗体を同定するための改良されたウェスタンブロット試験
AU6233296A (en) Diagnostic test for equine arteritis virus mediated disease

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140205